Over the last 12 months, Tenaya Therapeutics insiders reported no purchases and 14 sales totaling $6.0M across SEC Form 4 filings.
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | Ali FarazChief Executive Officer · O·D | ▼ Sale | 22,232 | $0.71 | $16K | -5.1% | 4 tranches |
| Aug 17, 2026 | Tingley WhittemoreChief Medical Officer · O | ▼ Sale | 7,424 | $0.71 | $5K | -3.4% | 4 tranches |
| Feb 25, 2026 | COLUMN GROUP III GP, LP10% | ▼ Sale | 4,170,266 | $0.57 | $2.4M | -100% | 4 tranches · indirect |
| Feb 23, 2026 | COLUMN GROUP III GP, LP10% | ▼ Sale | 829,734 | $0.61 | $505K | -27.3% | 4 tranches · indirect |
| Feb 17, 2026 | Higa TomohiroSVP, Finance · O | ▼ Sale | 3,469 | $0.64 | $2K | -2.8% | 3 tranches |
| Feb 17, 2026 | Ali FarazChief Executive Officer · O·D | ▼ Sale | 14,862 | $0.64 | $10K | -3.2% | 3 tranches |
| Feb 17, 2026 | Tingley WhittemoreChief Medical Officer · O | ▼ Sale | 5,160 | $0.64 | $3K | -2.3% | 3 tranches |
| Feb 11, 2026 | COLUMN GROUP III GP, LP10% | ▼ Sale | 4,400,290 | $0.69 | $3.0M | -62.4% | 4 tranches · indirect |
| Nov 17, 2025 | Higa TomohiroSVP, Finance · O | ▼ Sale | 1,367 | $1.33 | $2K | -1.4% | — |
| Nov 17, 2025 | Tingley WhittemoreChief Medical Officer · O | ▼ Sale | 2,877 | $1.33 | $4K | -1.7% | — |
| Nov 17, 2025 | Ali FarazChief Executive Officer · O·D | ▼ Sale | 3,126 | $1.33 | $4K | -1% | — |
| Aug 18, 2025 | Tingley WhittemoreChief Medical Officer · O | ▼ Sale | 5,053 | $1.25 | $6K | -2.8% | 3 tranches |
| Aug 18, 2025 | Ali FarazChief Executive Officer · O·D | ▼ Sale | 14,533 | $1.25 | $18K | -4.6% | 3 tranches |
| Aug 18, 2025 | Higa TomohiroSVP, Finance · O | ▼ Sale | 2,962 | $1.25 | $4K | -3% | 3 tranches |
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Tenaya Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $TNYA feed.